Dr. Scott Antonia talks about how we have made incredible progress in the field of immunology, but there is more work to be done. We have to do better because the prognosis for mesothelioma and other asbestos-related diseases is still poor. Dr. Antonia served as Chair of the Department of Thoracic Oncology and the leader of the Immunology Program at Moffitt Cancer Center.
Dr. Scott Antonia has worked extensively on gene modification to create a cancer vaccine that could be used at both the clinical and the pre-clinical levels.
What Makes Dr. Antonia Unique
Part of what makes Dr. Antonia unique is he holds two different medical technology patents, which he developed at Moffitt. He has also developed a translational research program, advancing immunotherapeutic strategies for asbestos-related cancers.
Dr. Scott Antonia’s focuses are immunobiology and immunotherapy. He has worked extensively on gene modification to create a cancer vaccine that could be used at both the clinical and the pre-clinical levels.
Dr. Scott Antonia has contributed to three strategies to combat asbestos-related cancers:
Genetically modified tumor cell vaccines
Genetically modified dendritic cell vaccines
Strategies developed to deal with tumor immunosuppression mechanisms
Dr. Scott Antonia has also strived to improve collaboration between the basic research scientists and the clinical research scientists in hopes of accelerating our search for a cure for these tragic diseases.